Compare ZEPP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZEPP | OMER |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 894.8M |
| IPO Year | 2017 | 2008 |
| Metric | ZEPP | OMER |
|---|---|---|
| Price | $19.78 | $11.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 116.4K | ★ 896.7K |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $887.39 | N/A |
| Revenue Next Year | $26.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.13 | $2.95 |
| 52 Week High | $61.50 | $17.65 |
| Indicator | ZEPP | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 52.45 |
| Support Level | $15.37 | $11.09 |
| Resistance Level | $25.82 | $12.57 |
| Average True Range (ATR) | 2.21 | 0.53 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 15.52 | 65.52 |
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.